DelveInsight’s “Ascites Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Ascites pipeline landscapes. It comprises Ascites pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ascites therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ascites pipeline products.
Some of the key takeaways of the Ascites Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such asGrifols S.A., BioVie Inc., Noorik Biopharmaceuticals, Clover Biopharmaceuticals, etc., are developing therapies for the treatment of Ascites.
-
Emerging therapies such as Albutein 20% Injectable Solution, BIV201, N-003, SCB-313, are expected to have a significant impact on the Ascites market in the coming years.
-
The growing incidence of Ascites is predicted to drive the expansion of the Ascites market.
-
The rise in the prevalence of cirrhosis and alcohol consumption is anticipated to drive the Ascites market.
Get an overview of pipeline landscape @ Ascites Clinical Trials Analysis
When over 25 millilitres (mL) of fluid builds up inside the abdomen, it’s referred to as ascites. Ascites usually occur when the liver stops working properly. When the liver malfunctions, fluid fills the space between the abdominal lining and therefore the organs.
Cirrhosis of the liver is the most typical reason behind ascites, but other conditions like heart failure, kidney failure, infection, or cancer also can cause the disease. Ascites are caused by a mixture of elevated pressure within the veins running through the liver (portal hypertension) and a decrease in liver function caused by scarring of the liver, i.e., cirrhosis.
Ascites Emerging Drugs
-
Albutein 20% Injectable Solution by Grifols S.A.
-
BIV201 by BioVie Inc.
-
N-003 by Noorik Biopharmaceuticals
-
SCB-313 by Clover Biopharmaceuticals
-
And others.
Scope of Ascites Pipeline Drug Insight
-
Coverage: Global
-
Major Players:Grifols S.A., BioVie Inc., Noorik Biopharmaceuticals, Clover Biopharmaceuticals, and others.
-
Pipeline Therapies: Albutein 20% Injectable Solution, BIV201, N-003, SCB-313, and others.
Table of Contents
|
1 |
Ascites Report Introduction |
|
2 |
Ascites Executive Summary |
|
3 |
Ascites Overview |
|
4 |
Ascites- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Ascites Pipeline Therapeutics |
|
6 |
Ascites Late Stage Products (Phase II/III) |
|
7 |
Ascites Mid Stage Products (Phase II) |
|
8 |
Ascites Early Stage Products (Phase I) |
|
9 |
Ascites Preclinical Stage Products |
|
10 |
Ascites Therapeutics Assessment |
|
11 |
Ascites Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Ascites Key Companies |
|
14 |
Ascites Key Products |
|
15 |
Ascites Unmet Needs |
|
16 |
Ascites Market Drivers and Barriers |
|
17 |
Ascites Future Perspectives and Conclusion |
|
18 |
Ascites Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s Ascites – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s ‘ Ascites- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Ascites epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/